Moving away from studies limited to melanoma cells, Wang et al. [31] studied the possible targeting of autophagy to increase the effectiveness of vemurafenib treatment using the anaplastic thyroid carcinoma BRAF-mutated FRO cell line as well as papillary thyroid carcinoma BRAF-mutated BCPAP cells. The gene discussed is BRAF; the disease is differentiated thyroid carcinoma.